Loading...
Jupiter Wellness, Inc.
JUPWW•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.32
$-0.08(-20.00%)

Financial performance has remained strong, with revenue growing from $132702.00 in Q4 2023 to $110213.00 in Q3 2024. Gross profit continued to perform well, with margins at -265% in the latest quarter. Operating income reached $0.00 in Q3 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$11.45M. Net income dropped to -$11.93M, keeping EPS at -$0.21. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan